Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| TVTX | Travere Therapeutics, Inc. | 2025-10-16 21:18:00 | 26.42 | -1.09 | -3.96 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TVTX | 0001438533 | Travere Therapeutics, Inc. | US89422G1076 | — | 262383102 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | CA | 3611 VALLEY CENTRE DR | SAN DIEGO | CA | 92130 | UNITED STATES | US | 888-969-7879 | 3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130 | 3611 VALLEY CENTRE DR, SAN DIEGO, CA, 92130 | Retrophin, Inc. | — | 2011 | — | — | — | 624,140,482 | 89,102,347 | 89,138,673 | Martin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016. | 2025-10-10 20:53:54 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 624,140,482 | -521,273,027 | -45.5096 | 88,739,826 | 12,641,341 | 16.6118 |
| 2023 | 1,145,413,509 | -393,357,757 | -25.5631 | 76,098,485 | 11,353,495 | 17.5357 |
| 2022 | 1,538,771,266 | 659,388,225 | 74.983 | 64,744,990 | 1,533,425 | 2.4259 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Peter Heerma | Chief Commercial Officer | 2024 | 503,750 | 0 | 299,155 | 353,500 | 14,697 | 1,513,360 |
| Jula Inrig | Chief Medical Officer | 2024 | 522,083 | 0 | 299,155 | 367,500 | 13,378 | 1,681,277 |
| Eric Dube | Chief Executive Officer, President, Director | 2024 | 822,000 | 0 | 1,607,400 | 865,200 | 14,697 | 5,204,877 |
| Christopher Cline | Chief Financial Officer | 2024 | 497,500 | 0 | 299,155 | 350,000 | 12,607 | 1,501,520 |
| Elizabeth Reed | Senior Vice President | 2023 | 468,417 | 0 | 648,327 | 230,300 | 14,917 | 2,018,708 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 385 |
| 2023 | 380 |
| 2022 | 462 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 233,175,000 | 145,238,000 | 212,018,000 |
| Cost Of Revenue | 7,744,000 | 11,450,000 | 7,592,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 217,496,000 | 244,990,000 | 7,500,000 |
| General And Administrative Expenses | 264,119,000 | 265,542,000 | 220,206,000 |
| Operating Expenses | 557,002,000 | 533,376,000 | 478,584,000 |
| Operating Income | -323,827,000 | -388,138,000 | -266,566,000 |
| Net Income | -321,545,000 | -111,399,000 | -278,482,000 |
| Earnings Per Share Basic | -4.08 | -1.5 | -4.37 |
| Earnings Per Share Diluted | -4.08 | -1.5 | -4.37 |
| Weighted Average Shares Outstanding Basic | 78,888,861 | 74,267,418 | 63,758,515 |
| Weighted Average Shares Outstanding Diluted | 78,888,861 | 74,267,418 | 63,758,515 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 58,535,000 | 58,176,000 | 61,688,000 |
| Marketable Securities Current | 73,325,000 | 248,638,000 | 285,526,000 |
| Accounts Receivable | 27,116,000 | 21,179,000 | 16,646,000 |
| Inventories | 6,200,000 | 9,410,000 | 6,922,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 416,702,000 | 616,775,000 | 486,437,000 |
| Marketable Securities Non Current | — | 260,037,000 | 103,031,000 |
| Property Plant And Equipment | 5,336,000 | 7,479,000 | 9,049,000 |
| Other Assets Non Current | 18,162,000 | 10,661,000 | 11,061,000 |
| Total Assets Non Current | 4,500,000 | 172,138,000 | 186,148,000 |
| Total Assets | 594,125,000 | 788,913,000 | 672,585,000 |
| Accounts Payable | 23,534,000 | 41,675,000 | 17,290,000 |
| Deferred Revenue | 2,815,000 | 7,096,000 | 11,976,000 |
| Short Term Debt | — | — | — |
| Other Liabilities Current | 14,291,000 | 5,237,000 | 5,722,000 |
| Total Liabilities Current | 200,751,000 | 177,908,000 | 142,163,000 |
| Long Term Debt | 310,310,000 | 377,263,000 | 375,545,000 |
| Other Liabilities Non Current | 6,796,000 | 8,485,000 | 9,385,000 |
| Total Liabilities Non Current | 334,297,000 | 410,195,000 | 487,571,000 |
| Total Liabilities | 535,048,000 | 588,103,000 | 629,734,000 |
| Common Stock | 9,000 | 7,000 | 6,000 |
| Retained Earnings | -1,447,167,000 | -1,125,622,000 | -1,014,223,000 |
| Accumulated Other Comprehensive Income | -80,000 | -1,456,000 | -2,907,000 |
| Total Shareholders Equity | 59,077,000 | 200,810,000 | 42,851,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 43,555,000 | 38,530,000 | 33,079,000 |
| Share Based Compensation Expense | 36,913,000 | 44,246,000 | 39,177,000 |
| Other Non Cash Income Expense | -7,944,000 | 3,626,000 | -972,000 |
| Change In Accounts Receivable | 6,001,000 | 11,264,000 | 682,000 |
| Change In Inventories | 3,771,000 | 39,420,000 | 2,064,000 |
| Change In Non Trade Receivables | 41,000 | 35,000 | 374,000 |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | -17,563,000 | 24,763,000 | 2,307,000 |
| Change In Other Liabilities | 5,646,000 | -418,000 | -1,723,000 |
| Cash From Operating Activities | -237,475,000 | -280,021,000 | -186,291,000 |
| Purchases Of Marketable Securities | 125,757,000 | 443,942,000 | 385,389,000 |
| Sales Of Marketable Securities | 326,334,000 | 334,575,000 | 382,000,000 |
| Acquisition Of Property Plant And Equipment | — | 668,000 | 191,000 |
| Acquisition Of Business | — | — | 0 |
| Other Investing Activities | 40,000 | 0 | 600,000 |
| Cash From Investing Activities | 99,325,000 | 55,776,000 | -32,553,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 134,738,000 | 191,198,000 | 2,978,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 139,422,000 | 218,752,000 | 117,573,000 |
| Change In Cash | 359,000 | -3,512,000 | -104,065,000 |
| Cash At End Of Period | 58,535,000 | 58,176,000 | 61,688,000 |
| Income Taxes Paid | 453,000 | 578,000 | 996,000 |
| Interest Paid | 8,838,000 | 8,838,000 | 10,159,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -4.08 | -1.5 | -4.37 |
| Price To Earnings Ratio | -4.2696 | -5.9933 | -4.8124 |
| Earnings Growth Rate | 172 | -65.6751 | 45.1827 |
| Price Earnings To Growth Ratio | -0.0248 | 0.0913 | -0.1065 |
| Book Value Per Share | 0.7489 | 2.7039 | 0.6721 |
| Price To Book Ratio | 23.2619 | 3.3249 | 31.2908 |
| Ebitda | -266,355,000 | -60,991,000 | -233,107,000 |
| Enterprise Value | 1,626,018,958.62 | 986,751,087.82 | 1,654,698,570.45 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 5.2526 | 1.8787 | 8.764 |
| Capital Expenditures | 41,412,000 | 36,960,000 | 31,022,000 |
| Free Cash Flow | -278,887,000 | -316,981,000 | -217,313,000 |
| Return On Equity | -5.4428 | -0.5547 | -6.4988 |
| One Year Beta | 1.2929 | 1.2364 | 1.0221 |
| Three Year Beta | 1.1011 | 1.0266 | 0.9484 |
| Five Year Beta | 0.9916 | 0.9908 | 1.0213 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Heerma Peter | CHIEF COMMERCIAL OFFICER | 2025-09-23 | 891 | D | 127,324 |
| REED ELIZABETH E | Chief Legal Officer and GC | 2025-09-22 | 10,000 | A | 99,878 |
| REED ELIZABETH E | Chief Legal Officer and GC | 2025-09-22 | 10,000 | D | 89,878 |
| REED ELIZABETH E | Chief Legal Officer and GC | 2025-09-22 | 10,000 | D | 40,000 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER | 2025-09-04 | 119 | D | 92,083 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Capital Advisors, Ltd. LLC | 2025-09-30 | 1,000 | 34 | 29.4118 |
| RICE HALL JAMES & ASSOCIATES, LLC | 2025-09-30 | 2,009,906 | 84,097 | 23.8999 |
| CWM, LLC | 2025-09-30 | 274,000 | 11,459 | 23.9113 |
| Farther Finance Advisors, LLC | 2025-09-30 | 2,725 | 114 | 23.9035 |
| VOYA INVESTMENT MANAGEMENT LLC | 2025-09-30 | 4,657,011 | 194,854 | 23.9 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| ETFis Series Trust I | 2025-07-31 | Virtus LifeSci Biotech Products ETF | BBP | 29,745 | 459,560.25 | 1.8647 |
| Advisors' Inner Circle Fund III | 2025-07-31 | I Shares | KCXIX | 392 | 6,056.4 | 0.0025 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 2025-07-31 | Invesco RAFI US 1500 Small-Mid ETF | PRFZ | 43,894 | 678,162.3 | 0.0286 |
| Global X Funds | 2025-07-31 | Global X Russell 2000 ETF | RSSL | 45,135 | 697,335.75 | 0.053 |
| LORD ABBETT SECURITIES TRUST | 2025-07-31 | Class F | LFMGX | 75,314 | 1,163,601.3 | 0.6489 |